Teva每月新注射的精神分裂症注射表明,在一次大型试验中,没有严重的副作用,可以改善病人的坚持治疗情况。 Teva's new monthly schizophrenia injection showed no serious side effects in a large trial and may improve patient adherence.

Teva制药公司报告说,在SOLARIS第3阶段对超过675名患有精神分裂症的成年人进行为期56周的为期一个月的ALANZAPINE LAI(TEV-749),在为期56周的试验中,在SOLARIS第3阶段没有发生注射后癫痫/沉睡综合症病例。 Teva Pharmaceuticals reported no cases of post-injection delirium/sedation syndrome in the Phase 3 SOLARIS trial for its once-monthly olanzapine LAI (TEV-749) over 56 weeks in over 675 adults with schizophrenia. 使用SteadyTeqTM技术的长效注射药的安全性与其他第二代抗精神病药物一致. The long-acting injectable, using SteadyTeq™ technology, showed a safety profile consistent with other second-generation antipsychotics. 另有数据显示,UZEDY(risperidone)与住院病人的住院时间比Invega Sustenna的住院时间短有关,但没有进行直接比较。 Separate data suggested UZEDY (risperidone) was linked to shorter hospital stays than Invega Sustenna in hospitalized patients, though no direct comparisons were made. 梯瓦强调了奥氮平 LAI 在改善每日服药作斗争的精神分裂症患者的治疗依从性和结果方面的潜力。 Teva highlighted the potential of olanzapine LAI to improve treatment adherence and outcomes for schizophrenia patients struggling with daily pills.